| Added by | JPPOUGET |
|---|---|
| Group name | EquipeJPP |
| Item Type | Journal Article |
| Title | Normal organ dosimetry for thyroid cancer patients treated with radioiodine as part of the multi-centre multi-national Horizon 2020 MEDIRAD project |
| Creator | Taprogge et al. |
| Author | Jan Taprogge |
| Author | Alex Vergara-Gil |
| Author | Francesca Leek |
| Author | Carla Abreu |
| Author | Lenka Vávrová |
| Author | Lily Carnegie-Peake |
| Author | Sarah Schumann |
| Author | Uta Eberlein |
| Author | Michael Lassmann |
| Author | Tino Schurrat |
| Author | Markus Luster |
| Author | Frederik A. Verburg |
| Author | Delphine Vallot |
| Author | Lavinia Vija |
| Author | Kate Newbold |
| Author | Manuel Bardičs |
| Author | Glenn Flux |
| Abstract | PURPOSE: Dosimetry is rarely performed for the treatment of differentiated thyroid cancer patients with Na[131I]I (radioiodine), and information regarding absorbed doses delivered is limited. Collection of dosimetry data in a multi-centre setting requires standardised quantitative imaging and dosimetry. A multi-national, multi-centre clinical study was performed to assess absorbed doses delivered to normal organs for differentiated thyroid cancer patients treated with Na[131I]I. METHODS: Patients were enrolled in four centres and administered fixed activities of 1.1 or 3.7 GBq of Na[131I]I using rhTSH stimulation or under thyroid hormone withdrawal according to local protocols. Patients were imaged using SPECT(/CT) at variable imaging time-points following standardised acquisition and reconstruction protocols. Whole-body retention data were collected. Dosimetry for normal organs was performed at two dosimetry centres and results collated. RESULTS: One hundred and five patients were recruited. Median absorbed doses per unit administered activity of 0.44, 0.14, 0.05 and 0.16 mGy/MBq were determined for the salivary glands of patients treated at centre 1, 2, 3 and 4, respectively. Median whole-body absorbed doses for 1.1 and 3.7 GBq were 0.05 Gy and 0.16 Gy, respectively. Median whole-body absorbed doses per unit administered activity of 0.04, 0.05, 0.04 and 0.04 mGy/MBq were calculated for centre 1, 2, 3 and 4, respectively. CONCLUSIONS: A wide range of normal organ doses were observed for differentiated thyroid cancer patients treated with Na[131I]I, highlighting the necessity for individualised dosimetry. The results show that data may be collated from multiple centres if minimum standards for the acquisition and dosimetry protocols can be achieved. |
| Publication | European Journal of Nuclear Medicine and Molecular Imaging |
| Volume | 50 |
| Issue | 11 |
| Pages | 3225-3234 |
| Date | 2023-09 |
| Journal Abbr | Eur J Nucl Med Mol Imaging |
| Language | eng |
| DOI | 10.1007/s00259-023-06295-0 |
| ISSN | 1619-7089 |
| Library Catalog | PubMed |
| Extra | Number: 11 PMID: 37300572 PMCID: PMC10256579 |
| Tags | Dosimetry, Humans, Iodine Radioisotopes, Multicentre study, NaI, original, Radiometry, Salivary Glands, Scientific, Thyroid cancer, Thyroid Neoplasms |
| Date Added | 2023/11/23 - 12:44:33 |
| Date Modified | 2024/12/15 - 11:46:12 |
| Notes and Attachments | PubMed entry (Attachment) Texte intégral (Attachment) |
Institut de Recherche en Cancérologie de
